Recent Finacing
Recent Raise
Bitterroot Bio develops immunotherapies targeting the CD47/SIRPα pathway to modulate immune responses and reduce atherosclerotic plaque in cardiovascular disease.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
See the team members at Bitterroot Bio.
